Sam Waksal is back. Five years after the cancer drug company he founded was sold to Eli Lilly & Co. for $6.5 billion, and four years after he served jail time in an insider trading scandal that ensnared Martha Stewart, Waksal is again making moves in the biotechnology industry.
ImClone's Waksal back in biotech with plans for spinouts
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.